daily glp 1 agonist GLP-1 Receptor Agonists: An Alternative for Rapid-Acting Insulin? 21st Century GLP Classification of currently available glucagon-like

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies

Treat any advert for GLP-1 patches with caution , especially if it's being promoted by an influencer on social media or making bold claims about weight loss results

Association of glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials

We have myokines which are also signals from muscle that we don't really quite understand much, although some medications are now starting to address muscle health and block some of those signals that break down muscle

Background Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Review context for lean-mass and mitigation questions during GLP-1-based weight-loss treatment